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Abstract: In this study, a series of fourteen ring-substituted 8-hydroxyquinoline 
derivatives were prepared. The synthesis procedures are presented. The compounds were 
analyzed using RP-HPLC to determine lipophilicity. They were tested for their activity 
related to inhibition of photosynthetic electron transport (PET) in spinach (Spinacia 
oleracea L.) chloroplasts. Primary in vitro screening of the synthesized compounds was 
also performed against four mycobacterial strains and against eight fungal strains. Several 
compounds showed biological activity comparable with or higher than the standards 
isoniazid or fluconazole. For all the compounds, the relationships between the lipophilicity 
and the chemical structure of the studied compounds are discussed. 
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1. Introduction 
A quinoline moiety is present in many classes of biologically-active compounds. A number of them 
have been used clinically as antifungal, antibacterial and antiprotozoic drugs [1,2], as well as 
antituberculotic agents [3–5]. Some quinoline-based compounds also show antineoplastic, 
antiasthmatic and antiplatelet activity [6–11]. A series of compounds derived from 8-hydroxyquinoline 
and styrylquinoline derivatives were recently synthesized as potential HIV-1 integrase inhibitors  
[12–15]. These compounds showed a significant similarity to some novel antifungal agents, namely 
homoallylamines. [16]. Our previous study dealing with 8-hydroxyquinoline and styrylquinoline 
derivatives showed that they could also possess strong antifungal activity [17,18]. According to the 
results reported recently, some new hydroxyquinoline derivatives also possess interesting herbicidal 
activities [17,19–22]. In addition, some of the investigated quinoline derivatives also showed 
antineoplastic activity [19,23]. 
Tuberculosis is a worldwide pandemic. About 1/3 of the world's population is infected with 
Mycobacterium tuberculosis, and every year almost 2 million people die as a result [24]. The 
Mycobacterium genus is composed of the M. tuberculosis complex and other species known as 
nontuberculous mycobacteria (NTM). In recent decades, the decrease in the prevalence of tuberculosis 
in developed countries has resulted in the increase in the proportion of diseases caused by NTM [25]. 
Among these species, the M. avium complex (MAC) has emerged as a major human pathogen, being a 
common cause of disseminated disease and death in patients with HIV/AIDS [26]. 
Chronic pulmonary disease is the most common clinical manifestation among the diseases caused 
by NTM, and the most common pathogens are the species belonging to the MAC, followed by  
M. kansasii. The clinical characteristics of NTM-related pulmonary disease are, in many cases, 
extremely similar to those of tuberculosis. Other clinical manifestations are caused principally by  
M. fortuitum, M. smegmatis and M. abscessus due to peritoneal infection as a result of catheterization, 
postsurgical infections, such as those following mammoplasty and heart transplant, as well as those 
following invasive procedures [27]. The above mentioned non-tuberculous strains are sometimes 
resistant to commonly used drugs (isoniazid, rifampicin, pyrazinamide) and other anti-tuberculous 
drugs [24], therefore systematic development of new effective compounds is necessary. Similarly, the 
discovery of new drugs for the treatment of systemic mycoses with novel modes of action due to the 
rapid growth of the immunocompromised patient population and development of resistance to the 
present azole therapies, and high toxicity of polyenes [28] is indispensable. It should be stressed that 
hydroxyquinoline and its derivatives were introduced as antifungal or antimycobacterial agents in 
clinical practice and novel compounds of this type are still investigated [3–5,29,30]. 
Over 50% of commercially available herbicides act by reversibly binding to photosystem II (PS II), 
a membrane-protein complex in the thylakoid membranes which catalyses the oxidation of water and 
the reduction of plastoquinone [31] and thereby inhibit photosynthesis [32–34]. Some organic 
compounds, e.g., substituted benzanilides [35] or substituted anilides of 2,6-disubstituted pyridine-4-
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thiocarboxamides [36] or pyrazine-2-carboxylic acids [37] were found to interact with tyrosine 
radicals TyrZ and TyrD which are situated in D1 and D2 proteins on the donor side of PS II and due to 
this interaction the photosynthetic electron transport is interrupted. 
This is a follow-up paper to our previous articles [12–15,17–23] dealing with syntheses and 
biological activities of ring-substituted quinoline derivatives. On the basis of formerly described 
azanaphtalenes we tried to search for new modifications of quinoline moiety that can trigger 
interesting biological activity. 
Primary in vitro screening of the synthesized compounds was performed against four mycobacterial 
strains and against eight fungal strains. The compounds were also tested for their photosynthesis-
inhibiting activity (the inhibition of photosynthetic electron transport) in spinach chloroplasts 
(Spinacia oleracea L.). Relationships among the structure and in vitro antimicrobial activities or/and 
inhibitory activity related to inhibition of photosynthetic electron transport (PET) in spinach 
chloroplasts of the new compounds are discussed. 
2. Results and Discussion 
2.1. Chemistry 
All studied compounds were prepared according to Scheme 1. Compounds 1-3 were obtained 
according to a previously described procedure [14]. Sulfonamides 4-7 were obtained from  
8-hydroxyquinoline through chlorosulfonation and amination. Compound 8 was obtained from 
commercially available 8-hydroxy-2-aminoquinoline by acylation in acetic anhydride. Styryquinolines 
9-14 were obtained from 5,7-dichloro-8-hydroxyquinaldine and the appropriate aldehyde in a two-step 
reaction in acetic anhydride followed by pyridine/water. 
Scheme 1. Synthesis of studied compounds. 
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Reagents and conditions: a) H2SO4/HNO3, Br2, Ac2O; b) ClSO3H, 0 °C; c) MeOH, amine;  
d) aldehyde, Ac2O, Py/H2O. 
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2.2. Lipophilicity 
Many low molecular weight drugs cross biological membranes through passive transport, which 
strongly depends on their lipophilicity. Lipophilicity is a property that has a major effect on 
absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) properties as well as 
pharmacological activity. Lipophilicity has been studied and applied as an important drug property for 
decades [38]. 
Table 1. Comparison of the calculated lipophilicities (log P/Clog P) with the determined 
log k values. 
N
OH
R
Comp. R log k log P/Clog P ChemOffice 
log P 
ACD/LogP 
1 5-NO2 0.5695 1.69 / 2.0836 2.00 ± 0.32 
2 5-SO3H-7-NO2 0.1479 0.37 / -0.703 1.70 ± 0.88 
3 5-SO3H-7-Br 0.3786 1.72 / -0.004 2.39 ± 0.91 
4 ON5-SO2  0.3293 0.61 / 1.43775 1.19 ± 0.81 
5 5-SO2NHCH(CH3)2 0.3373 2.17 / 2.5697 1.97 ± 0.78 
6 5-SO2NHC2H4Ph 0.3349 3.17 / 3.83597 3.29 ± 0.79 
7 5-SO2NHC4H8Ph 0.3902 4.09 / 4.74397 4.18 ± 0.78 
8 N NHO
O
O  
0.3583 1.33 / 0.93375 0.52 ± 0.73 
N
R
OH
Cl
Cl
Comp. R log k log P/Clog P ChemOffice 
log P 
ACD/LogP 
9 2-OH 1.5854 5.07 / 5.36425 5.62 ± 0.35 
10 4-OH 1.5866 5.07 / 5.36425 6.37 ± 0.36 
11 2,4-OH 1.5858 4.68 / 4.69725 5.65 ± 0.37 
12 3,5-OH 1.5867 4.68 / 4.69725 6.20 ± 0.37 
13 2-OH-5-OAc 1.5864 4.66 / 4.89345 4.87 ± 0.36 
14 N NOH
OH
Cl
Cl
Cl
Cl 2.5760 8.88 / 9.92051 10.50 ± 0.39 
 
Hydrophobicities (log P/Clog P) of the compounds 1-14 were calculated using two commercially 
available programs (ChemDraw Ultra 10.0 and ACD/LogP) and also measured by means of the  
RP-HPLC determination of capacity factors k with subsequent calculation of log k. The procedure was 
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performed under isocratic conditions with methanol as an organic modifier in the mobile phase using 
an end-capped non-polar C18 stationary RP column. The ChemDraw program did not resolve various 
lipophilicity values of individual positional isomers, that is, the same log P/Clog P data were 
calculated for 9/10 and 11/12. The results are shown in Table 1 and illustrated in Figure 1. 
Figure 1. Comparison of the computed log P/Clog P values using two programs with the 
calculated log k values. 
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The results obtained with all the compounds show that the experimentally-determined 
lipophilicities (log k) of compounds 1-14 are lower than those indicated by the calculated  
log P/Clog P, as shown in Figure 1. The results indicate that experimentally-determined log k values 
correlate relatively poorly with the calculated values. The correlation factors R2 yielded 0.83 for 
ChemOffice log P; 0.86 for ACD/LogP and 0.55 for ChemOffice Clog P respectively. 
These facts are probably caused by intramolecular interactions. As expected, compound 14 showed 
the highest lipophilicity, while compound 2 exhibited the lowest. The presence of the sulfonic acid 
moiety decreased the lipophilicity. Compound 6 showed less hydrophobicity compared with 5, 
contrary to the lipophilicity results calculated by software. This observation has been made previously 
[19]. Interesting results were obtained with subseries 9-13. Comparing the lipophilicity data log k of 
both OH-monosubstituted isomers 9 and 10, it can be stated that 4-hydroxy derivative 10 possessed 
higher hydrophobicity than 2-hydroxy isomer 9. This fact was predicted only by ACD/LogP. When  
OH-disubstituted compounds were compared, it was found that strong intramolecular interactions play 
a significant role. Hydrophobicity increased in the following order: 11 (2,4-OH) < 12 (3,5-OH). These 
results were also predicted by ACD/LogP. 
It can be assumed, that log k values specify lipophilicity within the individual series of studied 
compounds. Calculated log P data (ChemDraw) of compounds 1-8 corresponded with experimentally-
determined log k, while for compounds 9-14 there was better agreement between the calculated log P 
data (ACD/LogP) and experimentally-determined log k. 
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2.3. Biological activities 
The compounds under investigation could be divided into two groups based on their chemical 
structure. Group 1 included compounds 1-8, and Group 2 compounds 9-14. The compounds showed a 
wide range of biological activities and structure-activity relationships observations are interesting. All 
the results are shown in Table 2 and Table 3. 
Table 2. IC80 values related to PET inhibition in spinach chloroplasts in comparison with 
3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU) standard and in vitro antifungal activity 
(IC80) of compounds 1-10, 12 and 14 compared with fluconazole (FLU) standard.  
(ND = not determined due to insufficient solubility of the compound). 
Comp. PET reduction IC50 [μmol/L] 
MIC [µmol/L] 
CAa CTa CKa CGa TBa AFb ACb TMb 
24h 
48h 
24h 
48h 
24h 
48h 
24h 
48h 
24h 
48h 
24h 
48h 
24h 
48h 
72h 
120h
1 78.0 >500 >500 
>500 
>500
>500 
>500
>500 
>500
>500 
>500
>500 
>500 
>500 
>500 
>500
>500
2 ND >250 >250 
>250 
>250
>250 
>250
>250 
>250
>250 
>250
>250 
>250 
>250 
>250 
>250
>250
3 33.5 0.77 1.95 
1.95 
3.90 
3.90 
3.90 
1.95 
3.90 
3.90 
3.90 
0.77 
1.95 
7.80 
7.80 
1.95 
1.95 
4 ND 125 500 
500 
500 
250 
500 
500 
500 
500 
500 
500 
500 
125 
250 
250 
250 
5 54.4 125 250 
250 
250 
250 
250 
125 
250 
250 
500 
250 
250 
125 
125 
62.50
125 
6 304 125 125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
7 616 >125 >125 
>125 
>125
>125 
>125
>125 
>125
>125 
>125
>125 
>125 
>125 
>125 
>125
>125
8 306 15.60 62.50 
31.25
31.25
62.50
62.50
31.25
62.50
62.50
125 
62.50 
62.50 
62.50 
62.50 
62.50
62.50
9 ND >125 >125 
>125 
>125
>125 
>125
>125 
>125
>125 
>125
125 
125 
62.50 
125 
62.50
62.50
10 660 125 >125 
125 
>125
125 
>125
125 
>125
125 
>125
125 
125 
31.25 
62.50 
15.62
62.50
12 341 >125 >125 
>125 
>125
>125 
>125
>125 
>125
>125 
>125
125 
125 
62.50 
62.50 
15.62
15.62
14 334 0.98 3.90 
1.95 
7.81 
0.98 
1.95 
0.49 
1.95 
3.90 
15.62
3.90 
15.62 
15.62 
31.25 
3.90 
7.81 
DCMU 1.9 – – – – – – – – 
FLU – 0.06 0.12 
0.12 
>125
3.91 
15.62
0.98 
3.91 
0.24 
0.48 
>125 
>125 
>125 
>125 
1.95 
3.91 
The MIC determination was performed according to the CLSI reference protocol:  
a M27-A2 for yeasts (IC80 value) and b M38-A for moulds (IC50 value). 
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2.3.1. Inhibition of photosynthetic electron transport (PET) in spinach chloroplasts 
Quinoline derivatives 1-10, 12 and 14 showed a wide range of activity related to inhibition of 
photosynthetic electron transport (PET) in spinach chloroplasts, see Table 2. Three compounds 
showed moderate inhibitory IC50 values: 33.5 µmol/L (3), 54.4 µmol/L (5) and 78.0 µmol/L (1) while 
the activity of all the other studied compounds was very low. PET inhibition by 2, 4 and 9 could not be 
determined due to precipitation of the compounds during the experiments. 
The highest PET inhibition was shown by compounds 3, 5 and 1 with suitable aqueous solubility as 
well as lipophilicity. The sulfonic acid moiety contributed to enhanced aqueous solubility whereas  
a 7-bromo moiety (compound 3) increased the lipophilicity. Herbicidal effects of organic compounds 
with bromo or nitro substituents were observed previously [39]. Bulkiness and rigidity of the chain in 
the R substituent play a fundamental role in the series of sulfonamides 4-7, in addition to lipophilicity 
and water-solubility. The least lipophilic morpholine derivative 4 did not show any activity. On the 
other hand, phenylbutyl substitution in compound 7 is probably too bulky for it to reach the site of 
action in the photosynthetic electron transport chain and thus the inhibitory activity of this compound 
is low. Within the sulfonamide series the isopropyl substituent was the most advantageous from the 
aspect of effective PET inhibition and further lipophilicity increase caused reduction of inhibitory 
activity. On the other hand, great differences in the activity of compounds characterized with rather 
small differences in the lipophilicity (the log k values of compounds belonging to Group 1) indicate 
that the position of substituents and their electronic Hammett's parameters σ (especially electron-
withdrawing effect) seem to be also important for biological activity. Lipophilicity of the discussed 
compounds is only a secondary parameter influencing PET-inhibiting activity. In general, Group 2 
compounds exhibited only slight inhibition of PET and IC50 values determined for three compounds do 
not enable conclusions about structure-activity relationships. 
2.3.2. In vitro antifungal susceptibility testing 
Quinoline derivatives 1-10, 12 and 14 were tested for their in vitro antifungal activity. The results 
are shown in Table 2. Two compounds 3 and 14 showed very high antifungal activity, comparable or 
higher than the standard fluconazole. 
Generally, Group 1 showed lower biological activity than Group 2, although compound 3 
demonstrated high activity against all fungal strains. Compounds 1, 2, 4-7 did not show any antifungal 
activity. Compound 8 showed only moderate activity especially against Candida albicans ATCC 
44859. 
Unfortunately due to general low activity, no thorough structure-activity relationships (SAR) can be 
established. Nevertheless, an interesting relationship can be observed. According to the results 
presented in Tables 1 and 2 it can be concluded that bulky substituents and low lipophilicity decreased 
antifungal activity. A bromo moiety (compound 3) seems to be very important for high antifungal 
effect, as was reported recently [17]. Contrary to all expectations [18], compounds with a nitro moiety 
(i.e., 1, 2) did not show any activity. It can be concluded that relatively minor differences in 
lipophilicity were correlated with major differences in the activity of compounds. This suggests that 
for biological activity, the position of substituents and their electronic Hammett's parameters σ seem to 
be important. Similar observations were made with the PET-inhibiting activity. 
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Compound 14 showed the highest antifungal activity within Group 2. The compounds 9-12 showed 
only a moderate activity especially against Absidia corymbifera 272 and Trichophyton mentagrophytes 
445. Contrary to all expectations [18], 9 (2-OH substitution) possessed less activity than 10 and 12  
(4-OH or 3,5-OH respectively). This fact is probably caused by low solubility of 9. Lipophilicity is 
probably an important parameter influencing the activity. 
2.3.3. In vitro antimycobacterial evaluation 
Six compounds within Group 2 9-14 were evaluated for their in vitro antimycobacterial activity 
against four mycobacterial strains. The results are shown in Table 3. Compound 12 (3,5-OH) did not 
exhibit any significant antimycobacterial activity and compounds 9-11, 13 showed only medium 
and/or moderate activities. Nevertheless, compound 14 had an interesting MIC especially against  
M. smegmatis, M. kansasii and M. absessus. This compound was more active than the standard 
pyrazinamide (PZA) and in case of M smegmatis, its activity was comparable with the standard 
isoniazid (INH). 
Table 3. Antimycobacterial activity MIC/IC90 [µg/mL] of compounds 9-14 in comparison 
with the standards, pyrazinamide (PZA) and isoniazid (INH). 
Comp. MIC/IC90 [µg/mL] M. smegmatis M. absessus M. kansasii M. avium complex 
9 100 >300 >300 >300 
10 150 >300 >300 >300 
11 100 >100 >100 >100 
12 >100 >300 >300 >300 
13 100 >300 >300 >300 
14 40 130 40 >300 
PZA >100 >100 >100 >100 
INH 39 >100 <10 <10 
 
Due to medium and/or moderate activity of the majority of evaluated compounds, it is difficult to 
determine simple structure-activity relationships. According to Tables 1 and 3, it can be concluded that 
lipophilicity (log k) and other physico-chemical parameters only influence secondary characteristics of 
the compounds. 
3. Conclusions 
A series of fourteen ring-substituted 8-hydroxyquinolines were prepared and characterized. 
Compounds 1,3-14 are original new structures. All the prepared quinoline derivatives were analyzed 
using a RP-HPLC method for the measurement of lipophilicity and their lipophilicity was determined. 
The prepared compounds were tested for their antifungal and antimycobacterial activity and for their 
activity related to the inhibition of photosynthetic electron transport (PET) in spinach chloroplasts 
(Spinacia oleracea L.). 7-Bromo-8-hydroxyquinoline-5-sulfonic acid (3) and 5,7-dichloro-2-(2-{4-[2-
(5,7-dichloro-8-hydroxy-quinolin-2-yl)vinyl]phenyl}vinyl)quinolin-8-ol (14) possessed the highest in 
vitro antifungal activity and 3 and 8-hydroxyquinoline-5-sulfonic acid isobutylamide (5) showed the 
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highest PET-inhibiting activity. Compound 14 showed the highest antimycobacterial activity. In 
general, compounds 3 and 14 showed the highest inhibitory effects within the series. 
4. Experimental 
4.1. General 
All reagents were purchased from Aldrich. Kieselgel 60, 0.040-0.063 mm (Merck, Darmstadt, 
Germany) was used for column chromatography. TLC experiments were performed on alumina-
backed silica gel 40 F254 plates (Merck, Darmstadt, Germany). The plates were illuminated under UV  
(254 nm) and evaluated in iodine vapour. The melting points were determined on Boetius PHMK 05 
(VEB Kombinat Nagema, Radebeul, Germany) and are uncorrected. Elemental analyses (E.A.) were 
carried out on an automatic Perkin-Elmer 240 microanalyser (Boston, MA, USA) for C, H, N and are 
within 0.4% of theoretical values. The purity of the final compounds was checked by the HPLC 
separation module Waters Alliance 2695 XE (Waters Corp., Milford, MA, USA). The detection 
wavelength 210 nm was chosen. The peaks in the chromatogram of the solvent (blank) were deducted 
from the peaks in the chromatogram of the sample solution. The purity of individual compounds was 
determined from the area peaks in the chromatogram of the sample solution. UV spectra (λ, nm) were 
determined on a Waters Photodiode Array Detector 2996 (Waters Corp., Milford, MA, USA) in ca 
6×10-4 mol methanolic solution and log ε (the logarithm of molar absorption coefficient ε) was 
calculated for the absolute maximum λmax of individual target compounds. All 1H-NMR spectra were 
recorded on a Bruker AM-500 (499.95 MHz for 1H), and 13C-NMR spectra were recorded on a Bruker 
AM-400 (100 MHz) instrument (Bruker BioSpin Corp., Germany). Chemicals shifts are reported in 
ppm (δ) with reference to internal Si(CH3)4, when diffused easily exchangeable signals are omitted. 
4.2. Synthesis 
5-Nitroquinolin-8-ol (1). Yield: 25% of a yellow crystalline compound; Mp. 179-180 °C; HPLC purity 
98.09%; UV (nm), λmax/log ε: 398.4/3.67) [14]. 
 
8-Hydroxy-7-nitroquinoline-5-sulfonic acid (2). Yield: 54% of a bright yellow crystalline compound; 
Mp. 265 °C; HPLC purity 97.97%; UV (nm), λmax/log ε: 427.9/3.71) [40]. 
 
7-Bromo-8-hydroxyquinoline-5-sulfonic acid (3). Yield: 25% of a beige crystalline compound; Mp. 
280 °C; HPLC purity 98.32%; UV (nm), λmax/log ε: 264.2/3.69) [14]. 
 
5-(Morpholine-4-sulfonyl)quinolin-8-ol (4). 8-Hydroxyquinoline-5-sulfonyl chloride (2.4 g, 0.01 mol) 
was dissolved in dry MeOH (30 mL) and heated to reflux. Then morpholine (1.75 mL, 0.02 mol) was 
added dropwise. After 2 h of heating the resulted mixture was concentrated in vacuo and the resulting 
brown oil put into dichloromethane (45 mL). The orange precipitate formed was filtered off and 
recrystallized from MeOH. Yield 73% of a light yellow crystalline compound; Mp. 172 °C; E.A. 
Calcd.: C 54.53%, H 5.23%, N 9.08%; found: C 54.26%, H 5.31%, N 9.27%; HPLC purity 97.89%; 
UV (nm), λmax/log ε: 264.0/3.65; 1H-NMR (DMSO-d6), δ: 2.52 (s, 1H), 3.03 (t, J = 4.6 Hz, 4H), 3.70 
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(t, J = 4.7 Hz, 4H), 6.95 (d, J = 7.9 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 9.10 (d,  
J = 8.4 Hz, 2H). 
 
8-Hydroxyquinoline-5-sulfonic acid isobutylamide (5). 8-Hydroxyquinoline-5-sulfonyl chloride (2.2 g, 
0.01 mol) was dissolved in dry MeOH (30 mL) and heated to reflux. Then 2-butylamine (2.02 mL,  
0.02 mol) was added dropwise. After 2 h of heating a yellow solid was precipitated from the reaction 
mixture. After cooling the solid was filtered and crystallized from MeOH. Yield 50% of a yellow 
crystalline compound; Mp. 151 °C; E.A. Calcd.: C 55.70%, H 5.75%, N 9.99%; found: C 55.67%,  
H 5.63%, N 9.84%; HPLC purity 97.29%; UV (nm), λmax/log ε: 265.2/3.64; 1H-NMR (DMSO-d6), δ: 
0.85 (t, J = 7.4 Hz, 3H), 1.05 (d, J = 6.4 Hz, 1H), 1.50 (m, 2H), 2.50 (s, 1H), 2.95 (m, 1H), 6.95 (d,  
J = 8.0 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 9.05 (d, J = 7.6 Hz, 1H), 9.10 (d, J = 7.3 Hz, 2H). 
 
8-Hydroxyquinoline-5-sulfonic acid (2-phenylethyl)amide (6). Obtained in similar way to 4 from  
8-hydroxyquinoline-5-sulfonyl chloride and phenylethylamine. Yield: 25% of a yellow crystalline 
compound; Mp. 104 °C; E.A. Calcd.: C 62.18%, H 4.91%, N 8.53%; found: C 62.32%, H 4.86%,  
N 8.71%. HPLC purity 97.37%; UV (nm), λmax/log ε: 265.5/3.68; 1H-NMR (DMSO-d6), δ: 1.38 (d,  
J = 6.7 Hz, 2H), 2.50 (t, J = 1.6 Hz, 1H), 2.66 (s, 1H), 6.90 (d, J = 7.8 Hz, 1H), 7.30-7.41 (m, 2H), 
7.72 (d, J = 8.0 Hz, 2H), 8.96 (d, J = 8.8 Hz, 1H), 7.42-7.44 (m, 5H), 7.25 (d, J = 7.5 Hz, 1H). 
 
8-Hydroxyquinoline-5-sulfonic acid (4-phenylbutyl)amide (7). Obtained in similar way to 4 from  
8-hydroxyquinoline-5-sulfonyl chloride and 4-phenylbuthylamine. Yield: 55% of a yellow crystalline 
compound; Mp. 125 °C; E.A. Calcd: C 64.84%, H 5.99%, N 7.56%; found: C 65.02%, H 5.85%,  
N 7.69%; HPLC purity 98.60%; UV (nm), λmax/log ε: 265.3/3.68; 1H-NMR (DMSO-d6), δ: 1.44-1.58 
(m, 2H), 2.49 (s, 1H), 2.67 (t, J = 6.8 Hz, 1H), 6.95 (d, J = 7.9 Hz, 1H), 2.56 (t, J = 7.2 Hz, 2H), 7.18 
(d, J = 6.8 Hz, 1H), 7.24 (t, J = 7.0 Hz, 5H), 7.54-7.58 (m, 2H), 7.82 (d, J = 7.8 Hz, 1H), 9.06 (d,  
J = 8.5 Hz, 1H), 9.12 (d, J = 8.5 Hz, 2H). 
 
2-Acetylaminoquinolin-8-yl acetate (8). 2-Amino-8-hydroxyquinoline (2.5 g, 0.01 mol) and acetic 
anhydride (4 g, 3 mL, 0.04 mol) was mixed and heated in the microwave reactor at the boiling point 
for 5 min, then evaporated until dryness. Crude product was recrystalized from EtOH and dried. Yield: 
53% of a white crystalline compound; Mp. 120-126 °C; HPLC purity 99.69%; UV (nm), λmax/log ε: 
258.3/3.69; E.A. Calcd: C 63.93%, H 4.95%, N 11.47%; found: C 63.82%, H 4.56%, N 11.25%;  
1H-NMR (DMSO-d6), δ: 2.19 (s, 3H), 2.22 (s, 3H), 7.45 (m, 2H), 7.61 (d, J = 8.65Hz, 1H), 7.8 (t,  
J = 9.5Hz, 1H), 8.37 (d, J = 9.0Hz, 1H), 10.5 (s, 1H). 
4.2.1. General method for synthesis of compounds 9-14. 
To quinaldine (0.01 mol) in acetic anhydride (30 mL) an appropriate aldehyde (0.04 mol) was 
added and resulting mixture was heated under reflux for 24 h. Then, the liquid was evaporated in 
vacuo, pyridine (30 mL) and water (10 mL) were added and the mixture further heated for 3 h under 
reflux. Then mixture was evaporated to dryness and solid was taken up in dichloromethane and 
filtered. Crude product was recrystalized from EtOH and dried. 
Molecules 2010, 15                            
 
 
298
5,7-Dichloro-2-[2-(2-hydroxyphenyl)vinyl]quinolin-8-ol (9). Yield 87% of a beige crystalline 
compound; Mp. 141 °C; E.A. Calcd.: C 61.47%, H 3.34%, N 4.22%; found: C 61.87%, H 3.05%,  
N 4.12%; HPLC purity 98.10%; UV (nm), λmax/log ε: 309.9/3.61; 1H-NMR (DMSO-d6), δ: 6.88 (t,  
J = 7.4 Hz, 1H, phenyl), 6.95 (d, J = 8.1 Hz, 1H, phenyl), 7.20 (t, J = 7.7 Hz, 1H, phenyl), 7.57 (d,  
J = 16.3 Hz, 1H, vinyl), 7.61 (d, J = 7.7 Hz, 1H, phenyl), 7.68 (s, 1H, quinaldine), 7.93 (d, J = 8.8 Hz, 
1H, quinaldine), 8.23 (d, J = 16.3 Hz, 1H, vinyl), 8.39 (d, J = 8.8 Hz, 1H, quinaldine), 10.08 (s, 1H, 
OH), 10.46 (bs, 1H, OH); 13C-NMR (DMSO-d6), δ: 116.01, 116.66, 119.63, 119.93, 122.19, 123.40, 
123.94, 127.22, 127.84, 129.10, 130.56, 133.06, 133.55, 139.35, 149.11, 156.57, 156.74. 
 
5,7-Dichloro-2-[2-(4-hydroxyphenyl)vinyl]quinolin-8-ol (10). Yield 86% of a beige crystalline 
compound; Mp. 198 °C; E.A. Calcd.: C 61.47%, H 3.34%, N 4.22%; found: C 61.54%, H 3.32%,  
N 4.28%; HPLC purity 98.52%; UV (nm), λmax/log ε: 309.9/3.58; 1H-NMR (DMSO-d6), δ: 6.85 (d,  
J = 7.2 Hz, 2H, phenyl), 7.28 (d, J = 16.0 Hz, 1H, vinyl), 7.56 (d, J = 7.3 Hz, 2H, phenyl), 7.69 (d,  
J = 1.7 Hz, 1H, quinaldine), 7.86 (dd, J = 1.2 Hz, J = 8.8 Hz, 1H, quinaldine), 8.18 (d, J = 16.1 Hz, 
1H, vinyl), 8.40 (dd, J = 1.3 Hz, J = 8.8 Hz, 1H, quinaldine), 9.84 (s, 1H, OH), 10.30 (bs, 1H, OH); 
13C-NMR (DMSO-d6), δ: 115.17, 115.73, 119.02, 122.07, 123.19, 123.41, 126.41, 127.14, 128.97, 
132.97, 136.53, 138.66, 148.36, 155.67, 158.52. 
 
5,7-Dichloro-2-[2-(2,4-dihydroxyphenyl)vinyl]quinolin-8-ol (11). Yield 83% of a beige crystalline 
compound; Mp. 102-1030 °C; HPLC purity 98.96%; UV (nm), λmax/log ε: 321.9/3.65 [41]. 
 
5,7-Dichloro-2-[2-(3,5-dihydroxyphenyl)vinyl]quinolin-8-ol (12). Yield 93% of a beige crystalline 
compound; Mp. 206 °C; HPLC purity 98.59%; UV (nm), λmax/log ε: 314.5/3.68 [42]. 
 
5,7-Dichloro-2-[2-(2-hydroxy-5-acetoxyphenyl)vinyl]quinolin-8-ol (13). Yield 93% of a beige 
crystalline compound; Mp. 205-206 °C; E.A. Calcd.: C 31.62%, H 1.59%, N 3.69%; found:  
C 33.00%, H 2.35%, N 3.72%; HPLC purity 98.58%; UV (nm), λmax/log ε: 345.1/3.63; 1H-NMR 
(CDCl3), δ: 2.34 (s, 3H, CH3), 7.22 (d, J = 16.4Hz, 1H, vinyl), 7.85 (d, J = 16.4 Hz, 1H, vinyl), 7.40 (s, 
1H, quinaldine), 6.61 (d, J = 8.7 Hz, 1H, quinaldine), 8.15 (d, J = 8.7 Hz, 1H, quinaldine), 7.54 (d,  
J = 8.8 Hz, 1H, phenyl), 7.31 (d, J = 2.7 Hz, 1H, phenyl), 6.81 (dd, J = 2.7 Hz, J = 8.7 Hz, 1H, 
phenyl); 13C-NMR (CDCl3), δ: 25.58, 115.27, 117.31, 119.97, 120.64, 121.21, 122.78, 123.24, 124.79, 
127.43, 128.00, 129.01, 130.43, 133.97, 138.81, 147.84, 144.99, 152.21, 155.71, 177.45. 
 
5,7-Dichloro-2-(2-{4-[2-(5,7-dichloro-8-hydroxyquinolin-2-yl)vinyl]phenyl}vinyl)quinolin-8-ol (14). 
Yield 69% of a dark brown crystalline compound; Mp. 300 °C; HPLC purity 98.68%; UV (nm), 
λmax/log ε: 309.9/3.67 [42]. 
4.3. Lipophilicity determination by HPLC (capacity factor k/calculated log k) 
A Waters Alliance 2695 XE HPLC separation module and Waters Photodiode Array Detector 2996 
(Waters Corp., Milford, MA, USA) were used. A Symmetry® C18 5 μm, 4.6 × 250 mm, Part No. 
WAT054275, (Waters Corp., Milford, MA, USA) chromatographic column was used. The HPLC 
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separation process was monitored by Millennium32® Chromatography Manager Software, Waters 
2004 (Waters Corp., Milford, MA, USA). A mixture of MeOH p.a. (55.0%) and H2O-HPLC–  
Mili-Q Grade (45.0%) was used as a mobile phase. The total flow of the column was 0.9 mL/min, 
injection 30 μL, column temperature 30 °C and sample temperature 10 °C. The detection wavelength 
210 nm was chosen. The KI methanolic solution was used for the dead time (tD) determination. 
Retention times (tR) were measured in minutes. 
The capacity factors k were calculated using the Millennium32® Chromatography Manager 
Software according to formula k  =  (tR - tD)/tD, where tR is the retention time of the solute, whereas tD 
denotes the dead time obtained via an unretained analyte. Log k, calculated from the capacity factor k, 
is used as the lipophilicity index converted to log P scale. The log k values of the individual 
compounds are shown in Table 1. 
4.4. Lipophilicity calculations 
Log P, i.e. the logarithm of the partition coefficient for n-octanol/water, was calculated using the 
programs CS ChemOffice Ultra ver. 10.0 (CambridgeSoft, Cambridge, MA, USA) and ACD/LogP ver. 
1.0 (Advanced Chemistry Development Inc., Toronto, Canada). Clog P values (the logarithm of  
n-octanol/water partition coefficient based on established chemical interactions) were generated by 
means of CS ChemOffice Ultra ver. 10.0 (CambridgeSoft, Cambridge, MA, USA) software. The 
results are shown in Table 1. 
4.5. In vitro antifungal susceptibility testing 
The broth microdilution test [43–45] was used for the assessment of in vitro antifungal activity of 
the synthesized compounds against Candida albicans ATCC 44859 (CA), Candida tropicalis 156 
(CT), Candida krusei ATCC 6258 (CK), Candida glabrata 20/I (CG), Trichosporon beigelii 1188 
(TB), Aspergillus fumigatus 231 (AF), Absidia corymbifera 272 (AC), and Trichophyton 
mentagrophytes 445 (TM). Fluconazole (FLU) was used as the standard of a clinically used 
antimycotic drug. The procedure was performed with twofold dilution of the compounds in RPMI 
1640 (Sevapharma a.s., Prague, Czech Republic) buffered to pH 7.0 with 0.165 mol of 3-morpholino-
propane-1-sulfonic acid (MOPS, Sigma, Germany). The final concentrations of the compounds ranged 
from 500 to 0.975 μmol/L. Drug–free controls were included. The MIC determination was performed 
according to the CLSI (formerly NCCLS) reference protocol M27-A2 for yeasts (IC80 value) and  
M38-A for moulds (IC50 value). IC80 and IC50 were defined as an 80% resp. 50% or greater reduction 
of growth in comparison with the control. The values of MICs were determined after 24 and 48 h of 
static incubation at 35 °C. For T. mentagrophytes, the final MICs were determined after 72 and 120 h 
of incubation. The results are summarized in Table 2. 
4.6. Study of inhibition photosynthetic electron transport (PET) in spinach chloroplasts 
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and 
Kralova [46]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was 
determined spectrophotometrically (Genesys 6, Thermo Scientific, USA) using an artificial electron 
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acceptor 2,6-dichlorophenol-indophenol (DCIPP) according to Kralova et al. [47] and the rate of 
photosynthetic electron transport was monitored as a photoreduction of DCPIP. The measurements 
were carried out in phosphate buffer (0.02 mol/L, pH 7.2) containing sucrose (0.4 mol/L), MgCl2 
(0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll content was 30 mg/L in these experiments and 
the samples were irradiated (~100 W/m2) from 10 cm distance with a halogen lamp (250 W) using  
a 4 cm water filter to prevent warming of the samples (suspension temperature 22 °C). The studied 
compounds were dissolved in DMSO due to their limited water solubility. The applied DMSO 
concentration (up to 4%) did not affect the photochemical activity in spinach chloroplasts. The 
inhibitory efficiency of the studied compounds was expressed by IC50 values, i.e., by molar 
concentration of the compounds causing 50% decrease in the oxygen evolution rate relative to the 
untreated control. The comparable IC50 value for a selective herbicide 3-(3,4-dichlorophenyl)-1,1-
dimethylurea, DCMU (Diurone®) was about 1.9 μmol/L [48]. The results are summarized in Table 2. 
4.7. In vitro antimycobacterial evaluation 
Clinical isolates of Mycobacterium avium complex CIT19/06, M. kansasii CIT11/06, M. absessus 
CIT21/06 and strain M. smegmatis MC2155 were grown in Middlebrook broth (MB), supplemented 
with OADC supplement (Oleic, Albumin, Dextrose, Catalase, Becton Dickinson, U.K.). Identification 
of these isolates was performed using biochemical and molecular protocols. At log phase growth, the 
10 mL culture was centrifuged at 15,000 RPM for 20 minutes using a bench top centrifuge (Model CR 
4-12 Jouan Inc U.K). Following the removal of the supernatant, the pellet was washed in fresh 
Middlebrook 7H9GC broth and re-suspended in 10 ml of fresh supplemented MB. The turbidity was 
adjusted to match McFarland standard No. 1 (3 × 108 cfu) with MB broth. A further 1:20 dilution of 
the culture was then performed in MB broth. 
The antimicrobial susceptibility of all four mycobacteria was investigated in 96 well plate format. 
Here, 300 µL of sterile deionised water was added to all outer-perimeter wells of the plates to 
minimize evaporation of the medium in the test wells during incubation. 100 µL of each dilution was 
incubated with 100 µL of each of the mycobacterial species. Dilutions of each compound were 
prepared in duplicate. For all synthesized compounds, final concentrations ranged from 300 µg/mL to 
10 µg/mL. All compounds were prepared in DMSO and subsequent dilutions were made in 
supplemented Middlebrook broth. The plates were sealed with parafilm and were incubated at 37 °C 
overnight in the case of M. smegmatis and M. absessus and for 5 days in the case of M. kansasii and 
M. avium complex. Following incubation, a 10% addition of alamarBlue (AbD Serotec) was mixed 
into each well and readings at 570 nm and 600 nm were taken, initially for background subtraction and 
subsequently after 24 hour re-incubation. The background subtraction is necessary with strongly 
coloured compounds which may interfere with the interpretation of any colour change. In  
non-interfering compounds, a blue colour in the well was interpreted as an absence of growth, and a 
pink colour was scored as growth. The MIC was initially defined as the lowest concentration which 
prevented a visual colour change from blue to pink. The results are shown in Table 3. 
The MIC for mycobacteria was defined as a 90% or greater (IC90) reduction of growth in 
comparison with the control. The MIC/IC90 value is routinely and widely used in bacterial assays and 
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is a standard detection limit according to the Clinical and Laboratory Standards Institute (CLSI, 
www.clsi.org/). 
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